No Data
Express News | Medicinova Chief Business Officer David H. Crean, Ph.d. Assumes Communications Role Overseeing Investor Engagement and Public Relations
Express News | Medicinova Receives Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for the Prevention of Metastasis of Various Solid Cancer
Express News | MediciNova Has Received A Notice Of Allowance From The US Patent And Trademark Office For A Pending Patent Application Covering MN-166 (Ibudilast) For The Prevention Of Metastasis In Various Cancers
MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting
The highlights of presentation are as follows:The primary endpoints were safety and tolerability of MN-166 and TMZ combination treatment and the efficacy of combination treatment.The combination of Te
Express News | MediciNova Inc: Combination of Temozolomide (Tmz) and Mn-166 Was Safe and Well Tolerated
Express News | Medicinova Announces Data From Phase 1B/2a Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (Asco) Annual Meeting 2024